Publications by authors named "E H Guthrie"
Background: Many patients with ulcerative colitis report ongoing diarrhoea even when their disease is stable and in remission.
Design: MODULATE was a pragmatic, multicentre, seamless, adaptive, phase 2/3 open-label, parallel-group, multiarm multistage randomised controlled trial.
Setting And Participants: People aged over 18 years with stable ulcerative colitis who had diarrhoea, recruited from secondary care sites in the United Kingdom.
Background: Low-dose amitriptyline, a tricyclic antidepressant (TCA), was superior to placebo for irritable bowel syndrome (IBS) in the AmitripTyline at Low-dose ANd Titrated for Irritable bowel syndrome as Second-line treatment (ATLANTIS) trial.
Objective: To perform post hoc analyses of ATLANTIS for predictors of response to, and tolerability of, a TCA.
Design: ATLANTIS randomised 463 adults with IBS to amitriptyline (232) or placebo (231).
Purpose: People with Persistent Physical Symptoms experience physical symptoms that are not wholly explained by a medical disorder or disease. Multidisciplinary treatment is recommended for people with severe difficulties and is provided in a small number of specialist centres in the UK. Only brief descriptions of this treatment are available, and the experiences of people receiving this treatment as an inpatient have not been explored.
View Article and Find Full Text PDFArticle Synopsis
- - The study aims to assess the effectiveness and cost-efficiency of low-dose amitriptyline as a second-line treatment for patients with irritable bowel syndrome (IBS) in primary care, especially when first-line treatments fail.
- - Conducted as a pragmatic, double-blind, placebo-controlled trial across 55 general practices in England, the design included both quantitative outcomes and qualitative experiences from participants and general practitioners regarding the treatment.
- - Participants included adults over 18 diagnosed with IBS who did not respond to initial therapies; they received either amitriptyline or a placebo for 6 months, with a focus on measuring the difference in IBS symptoms to see if the medication has a significant impact.
Background: Irritable bowel syndrome (IBS) can cause troublesome symptoms, which impact patients' quality of life and incur considerable health service resource use. Guidelines suggest low-dose amitriptyline for IBS as second-line treatment, but this is rarely prescribed in primary care.
Aim: To explore patients' and GPs' views and experiences of using low-dose amitriptyline for IBS.